Alcon acquires ophthalmic division

Article

Alcon will acquire the ophthalmic division of SensoMotoric Instruments (SMI).

Alcon will acquire the ophthalmic division of SensoMotoric Instruments (SMI).

SMI, a private company based in Germany, deals with ocular guidance technology such as real-time eye tracking, automatic registration of ocular imaging and IOL positing and alignment guidance.

Alcon will integrate SMI into its existing global cataract portfolio and will further develop existing products that improve patient outcomes in cataract surgery. This includes the IOL used to treat cataracts and correct refractive errors such as astigmatism and presbyopia.

Sabri Markabi, Senior Vice President of Research and Development at Alcon, commented, "This acquisition further strengthens Alcon's position in the cataract surgery market with an expansion into leading ocular tracking technology. The stare-of-the-art guidance technology provides surgeons with customization options and automated solutions, enabling optimal outcomes for their cataract patients including underlying refractive conditions."

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.